NCE-1 Intelligence & Market Opportunity

Forzinity

Elamipretide

Mitochondrial Dysfunction Agent

Subcutaneous Solution

Forzinity is a mitochondrial-targeted therapy for Barth syndrome in patients weighing 30 kg or more. It stabilizes mitochondrial function to improve energy production and muscle strength, administered via subcutaneous injection.

Approval Date

19-Sep-25

NCE-1 Date

19-Sep-29

NCE Date

19-Sep-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Elamipretide

Innovator

STEALTH BIOTHERAPEUTICS INC

Dosage Form

Subcutaneous Solution

Strength

EQ 280 mg base/3.5 mL (EQ 80 mg base/mL)

Therapeutic Category

Mitochondrial Dysfunction Agent

Usage

To improve muscle strength in patients with Barth syndrome weighing at least 30 kg

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets